Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385737555> ?p ?o ?g. }
- W4385737555 endingPage "1562" @default.
- W4385737555 startingPage "1544" @default.
- W4385737555 abstract "Resistance of melanoma to targeted therapy and immunotherapy is linked to metabolic rewiring. Here, we show that increased fatty acid oxidation (FAO) during prolonged BRAF inhibitor (BRAFi) treatment contributes to acquired therapy resistance in mice. Targeting FAO using the US Food and Drug Administration-approved and European Medicines Agency-approved anti-anginal drug ranolazine (RANO) delays tumour recurrence with acquired BRAFi resistance. Single-cell RNA-sequencing analysis reveals that RANO diminishes the abundance of the therapy-resistant NGFRhi neural crest stem cell subpopulation. Moreover, by rewiring the methionine salvage pathway, RANO enhances melanoma immunogenicity through increased antigen presentation and interferon signalling. Combination of RANO with anti-PD-L1 antibodies strongly improves survival by increasing antitumour immune responses. Altogether, we show that RANO increases the efficacy of targeted melanoma therapy through its effects on FAO and the methionine salvage pathway. Importantly, our study suggests that RANO could sensitize BRAFi-resistant tumours to immunotherapy. Since RANO has very mild side-effects, it might constitute a therapeutic option to improve the two main strategies currently used to treat metastatic melanoma." @default.
- W4385737555 created "2023-08-11" @default.
- W4385737555 creator A5001217593 @default.
- W4385737555 creator A5003094466 @default.
- W4385737555 creator A5005058607 @default.
- W4385737555 creator A5007234389 @default.
- W4385737555 creator A5009985796 @default.
- W4385737555 creator A5011961061 @default.
- W4385737555 creator A5015885258 @default.
- W4385737555 creator A5015939041 @default.
- W4385737555 creator A5018067231 @default.
- W4385737555 creator A5026773787 @default.
- W4385737555 creator A5031277613 @default.
- W4385737555 creator A5032449700 @default.
- W4385737555 creator A5034140517 @default.
- W4385737555 creator A5035197984 @default.
- W4385737555 creator A5037641911 @default.
- W4385737555 creator A5045175167 @default.
- W4385737555 creator A5052483618 @default.
- W4385737555 creator A5055965377 @default.
- W4385737555 creator A5058705198 @default.
- W4385737555 creator A5064003245 @default.
- W4385737555 creator A5064835137 @default.
- W4385737555 creator A5069693450 @default.
- W4385737555 creator A5071676196 @default.
- W4385737555 creator A5075567314 @default.
- W4385737555 creator A5082118845 @default.
- W4385737555 creator A5085139761 @default.
- W4385737555 creator A5089293571 @default.
- W4385737555 creator A5089380647 @default.
- W4385737555 creator A5089397863 @default.
- W4385737555 creator A5091638762 @default.
- W4385737555 date "2023-08-10" @default.
- W4385737555 modified "2023-10-17" @default.
- W4385737555 title "Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy" @default.
- W4385737555 cites W1163924930 @default.
- W4385737555 cites W1640505003 @default.
- W4385737555 cites W1724933401 @default.
- W4385737555 cites W1963627099 @default.
- W4385737555 cites W1979422503 @default.
- W4385737555 cites W2019544036 @default.
- W4385737555 cites W2019745630 @default.
- W4385737555 cites W2019943673 @default.
- W4385737555 cites W2033708806 @default.
- W4385737555 cites W2040722761 @default.
- W4385737555 cites W2053847949 @default.
- W4385737555 cites W2069089843 @default.
- W4385737555 cites W2072844557 @default.
- W4385737555 cites W2089370234 @default.
- W4385737555 cites W2133154786 @default.
- W4385737555 cites W2143163879 @default.
- W4385737555 cites W2145429129 @default.
- W4385737555 cites W2147148712 @default.
- W4385737555 cites W2148346557 @default.
- W4385737555 cites W2158416296 @default.
- W4385737555 cites W2257573908 @default.
- W4385737555 cites W2287840388 @default.
- W4385737555 cites W2300290254 @default.
- W4385737555 cites W2321587450 @default.
- W4385737555 cites W2322378248 @default.
- W4385737555 cites W2573158190 @default.
- W4385737555 cites W2587940603 @default.
- W4385737555 cites W2605233023 @default.
- W4385737555 cites W2612431515 @default.
- W4385737555 cites W2746892915 @default.
- W4385737555 cites W2750665224 @default.
- W4385737555 cites W2753432434 @default.
- W4385737555 cites W2755181857 @default.
- W4385737555 cites W2769260826 @default.
- W4385737555 cites W2773011778 @default.
- W4385737555 cites W2783011222 @default.
- W4385737555 cites W2794480084 @default.
- W4385737555 cites W2805619986 @default.
- W4385737555 cites W2884607428 @default.
- W4385737555 cites W2888346100 @default.
- W4385737555 cites W2896528350 @default.
- W4385737555 cites W2899951697 @default.
- W4385737555 cites W2931036699 @default.
- W4385737555 cites W2946052571 @default.
- W4385737555 cites W2946569365 @default.
- W4385737555 cites W2949177718 @default.
- W4385737555 cites W2950011075 @default.
- W4385737555 cites W2951506174 @default.
- W4385737555 cites W2964974081 @default.
- W4385737555 cites W2971445256 @default.
- W4385737555 cites W2972936715 @default.
- W4385737555 cites W2997280954 @default.
- W4385737555 cites W3011808378 @default.
- W4385737555 cites W3014932320 @default.
- W4385737555 cites W3040969771 @default.
- W4385737555 cites W3042107687 @default.
- W4385737555 cites W3047821845 @default.
- W4385737555 cites W3047951122 @default.
- W4385737555 cites W3110603364 @default.
- W4385737555 cites W3114800664 @default.
- W4385737555 cites W3125225606 @default.
- W4385737555 cites W3137653259 @default.
- W4385737555 cites W3145969289 @default.